CureVac (NASDAQ:CVAC) shares are trading higher after the company reported its vaccine candidate, CV2CoV, demonstrated high immunogenicity against virus variants in a preclinical study.

CureVac's stock has been rising Thursday, up 7.15% to a price of $99.34. Thursday the stock has been traded at a volume of 636.39 thousand, about 52.18% of its recent 30-day volume average of 1.22 million.

The moving average price of the stock over the past 50 days was $97.48 at the time this article was published. In the past fifty-two weeks, the stock price has been as high as $151.8 and as low as $43.0.

If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.